Search clinical trials for: EU-approved Cosentyx

Total 611 results

Bio-Thera Solutions

Active, not recruiting

Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

Plaque Psoriasis

China
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

Hungary, Serbia, Georgia, Russian Federation, Slovakia, Czechia, Bulgaria, Moldova, Republic of, Poland
Celltrion

Recruiting

A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects

Healthy Subjects

Korea, Republic of
Fresenius Kabi SwissBioSim GmbH

Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

Healthy

New Zealand
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects

Psoriasis

China
Pfizer
Hospira, now a wholly owned subsidiary of Pfizer

Completed

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

Neutropenia

Australia
Celltrion

Recruiting

To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

Estonia
Celltrion

Completed

Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects

Healthy Subjects

New Zealand
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11022 in Healthy Subjects

Healthy Subjects
Celltrion

Not yet recruiting

A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Celltrion

Completed

To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects

Healthy

Korea, Republic of
Novartis Pharmaceuticals

Recruiting

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis (SPARROW)

Moderate-to-severe Plaque Psoriasis

Russian Federation
Novartis Pharmaceuticals

Available

Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa (HS)
University of California, San Francisco
Novartis Pharmaceuticals

Completed

Immunologic Response to Secukinumab in Plaque Psoriasis

Psoriasis

United States
Celltrion

Completed

A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects

Healthy Male Subjects

Australia
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Psoriasis Vulgaris | Pustular Psoriasis | Psoriatic Arthritis

Japan
Novartis Pharmaceuticals

Active, not recruiting

A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Moderate to Severe Chronic Plaque Psoriasis

China
Beth Israel Deaconess Medical Center
Novartis Pharmaceuticals

Terminated

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

Necrobiosis Lipoidica Diabeticorum

United States
Massachusetts General Hospital
Novartis

Withdrawn

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

Discoid Lupus Erythematosus

United States
Diamant Thaci
Novartis

Completed

Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients (BIOMARKER)

Psoriasis Vulgaris

Germany
Tanja Todberg, MD

Unknown

Anti-IL-17 a New Treatment for Contact Dermatititis

Allergic Contact Dermatitits

Denmark
Novartis Pharmaceuticals

Completed

A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China (UNMASK2)

Psoriasis

China
Novartis Pharmaceuticals

Completed

An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

Plaque Psoriasis

United States
Mayo Clinic

Completed

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

PITYRIASIS RUBRA PILARIS

United States
Narrows Institute for Biomedical Research
Novartis

Unknown

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

Psoriasis Vulgaris

United States
Tufts Medical Center

Completed

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Chinese University of Hong Kong

Completed

PsA Secukinumab XCT Structural Progression Study

Psoriatic Arthritis

Hong Kong
Jinnah Postgraduate Medical Centre

Completed

Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.

Plaque Psoriasis

Pakistan
Gan and Lee Pharmaceuticals, USA

Completed

PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males

Diabetes Mellitus

Germany
University Hospital Southampton NHS Foundation...
Imperial College London; Public Health England

Completed

Safety of Nasal Influenza Immunisation in Egg Allergic Children (SNIFFLE)

Egg Hypersensitivity

United Kingdom
University of Pennsylvania
Novartis

Recruiting

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Psoriasis

United States
Vrije Universiteit Brussel
University of British Columbia; University of Coimbra; Amsterdam UMC, location... and other collaborators

Not yet recruiting

International Study to Evaluate a Navigation Program for Older People With Cancer and Their Family Caregivers (EU NAVIGATE Study) (EU NAVIGATE)

Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative
Celltrion

Completed

To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria (omalizumab)

Chronic Spontaneous Urticaria

Poland
Novartis Pharmaceuticals

Withdrawn

Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population

Psoriasis
mAbxience Research S.L.

Completed

A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers

Healthy Volunteers | Male | Japanese

Japan
University of North Carolina, Chapel Hill

Completed

A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers (IRB 09-0259)

Healthy | Cigarette Smoking

United States
Omega Ophthalmics

Completed

Clinical Investigation of Omega Refractive Capsule Model V With Use of an FDA Approved IOL (ORCV)

Cataract

Costa Rica
Kashiv BioSciences, LLC

Completed

To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects

Healthy

India
Celltrion

Completed

To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects

Healthy

Australia
Ruhr University of Bochum

Completed

Tachosil for the Prevention of Symptomatic Lymph Cysts

Cervical Cancer | Endometrial Cancer

Austria, Germany
AbbVie

Completed

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Celltrion

Completed

To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin

Healthy

Korea, Republic of
Adocia

Completed

A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes

Germany
Professor Mikkel Østergaard
Novartis Healthcare A/S

Unknown

Treat-to-target With Secukinumab in Axial Spondyloarthritis (TRACE)

Ankylosing Spondylitis | Axial Spondyloarthritis

Denmark
Janssen Research & Development, LLC

Completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4

Healthy

Belgium
ISU Abxis Co., Ltd.

Completed

A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

Gaucher Disease

Australia
University Hospital Inselspital, Berne

Completed

The Effect of Hyperglycaemia on Local Energy Stores in the Working Muscle in Patients With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1 | Exercise

Switzerland
James G. Krueger, MD, PhD
Novartis

Completed

Safety and Efficacy of Secukinumab in Mild Psoriasis

Psoriasis

United States
Northwestern University
Icahn School of Medicine at Mount Sinai

Completed

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

Netherton Syndrome | Ichthyosis | Lamellar Ichthyosis | Autosomal Recessive Congenital Ichthyosis | Congenital Ichthyosiform Erythroderma | Epidermolytic Ichthyosis

United States
Janssen Research & Development, LLC

Completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1 (PLATFORM)

Healthy

Belgium

3

Subscribe